<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01423708</url>
  </required_header>
  <id_info>
    <org_study_id>1956P</org_study_id>
    <secondary_id>2009-016176-78</secondary_id>
    <nct_id>NCT01423708</nct_id>
  </id_info>
  <brief_title>Everolimus in de Novo Liver Transplantation: a Multicentre Randomized Study</brief_title>
  <acronym>EPOCAL</acronym>
  <official_title>Terapia Con Everolimus Nel Trapianto de Novo di Fegato: Uno Studio Multicentrico Randomizzato</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera di Padova</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera di Padova</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety and Efficacy of Everolimus in adult de novo liver transplant recipients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective study was designed to evaluate the feasibility and effectiveness of the use
      of Everolimus in the minimization and possible suspension of calcineurin inhibitors in adult
      liver transplant patients. The study will take into account a control group (standard
      immunosuppression with tacrolimus and steroids) after induction with anti-IL2 Antibodies.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2010</start_date>
  <completion_date type="Anticipated">January 2014</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biopsy-proven rejection episodes (BPAR)</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Graft survival</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient post-Liver Transplantation survival</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Everolimus monotherapy</measure>
    <time_frame>30 days</time_frame>
    <description>Patients not requiring calcineurin inhibitors (CNI)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal function evaluation</measure>
    <time_frame>24 months</time_frame>
    <description>Impact of therapy on renal function, evaluated by creatinine clearance according to the Modification of Diet in Renal Disease (MDRD) Study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Requests for dialysis</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>24 months</time_frame>
    <description>Evaluation of common post Liver Transplantation Adverse Events:
wound healing, bone marrow depression, hyperlipidemia, proteinuria, diabetes mellitus, diagnosed hypertension, infections, levels of HCV.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">117</enrollment>
  <condition>Liver Failure</condition>
  <condition>Liver Diseases</condition>
  <condition>Liver Cirrhosis</condition>
  <condition>Liver Neoplasms</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard immunosuppression protocol with Tacrolimus, maintaining trough levels between 6 and 12 ng/ml in the first month, in association with steroids (20 mg/day with subsequent weaning within 3 months after transplantation).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Everolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of Everolimus in association with Tacrolimus and steroids.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Administration of Everolimus within 24 hours from the time of randomization (7 days from the time of transplantation) in association with Tacrolimus and steroids. The first dose level of the trough will be performed at day 7 after initiation of therapy. After the reaching an Everolimus trough level of &gt;5ng/ml (final target 6-12 ng/ml), there will be a gradual weaning of tacrolimus (bringing Tacrolimus blood levels &lt;5 ng/ml) with discontinuation of Tacrolimus within 30 days after transplantation when possible.</description>
    <arm_group_label>Everolimus</arm_group_label>
    <other_name>Certican</other_name>
    <other_name>Afinitor</other_name>
    <other_name>Zortress</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients between 18 and 70 years of age,

          -  Patients undergoing de novo liver transplantation from cadaveric donor with a
             functional graft at the time of randomization,

          -  Transplantation from cadaveric donor whole or split liver,

          -  Patients able to communicate properly with the study investigators, to understand and
             respond to the needs of the protocol and who have given written consent

          -  Cold ischemia time &lt;12 hours

        Exclusion Criteria:

          -  Physical or laboratory abnormalities or mental illness within 2 weeks before
             randomization such that, in the opinion of the investigator, may interfere with
             participation in the study

          -  Women who are pregnant (positive test with hCG values&gt; 5mUI/ml) or breast-feeding

          -  Women of childbearing potential, with the following exceptions: a) women in menopause
             (spontaneous amenorrhea for at least 12 months, spontaneous amenorrhea for at least 6
             months with FSH levels &gt;40 mIU/ml, surgical bilateral oophorectomy at least 6 weeks
             before baseline, with or without hysterectomy) b) women who use one or more reliable
             and approved methods of contraception for the duration of the study and for the three
             months following discontinuation of study treatment.

          -  Patients who undergo transplantation or multivisceral transplantation of pancreatic
             islets, or who have previously undergone organ transplantation or tissue.

          -  Patients who undergo combined liver-kidney transplantation

          -  Patients who undergo living donor liver transplantation

          -  Patients who undergo ABO-incompatible liver transplantation

          -  Patients who undergo transplantation from donors positive for HBV surface antigen or
             HIV

          -  History of malignant disease at any site in the 3 year period prior, regardless of
             whether or not there is evidence of recurrence or metastasis. (Except non-metastatic
             skin cancers such as basal cell or squamous cell carcinoma of the skin, or
             hepatocellular carcinoma)

          -  Patients receiving other investigational drugs within 4 weeks before baseline or who
             are currently enrolled in other clinical trials

          -  Patients who show hypersensitivity to the drug (or drugs similar to Everolimus -
             Former macrolides) or class or pharmaceutical excipients. Also, when there are
             contraindications

          -  A history of coagulopathy or the presence of any medical condition that requires
             long-term anticoagulant therapy after transplantation (The use of low-dose ASA is
             admissible)

          -  Platelet count &lt;=40.000/mm3 or WBC count &lt;2000/mm3 or hemoglobin &lt;=7g/dl at the time
             of randomization

          -  Severe systemic infections

          -  High cholesterol levels (&gt;350mg/dl) or severe hypertriglyceridemia (&gt;500mg/dl).
             Patients with compensated hyperlipidemia are eligible.

          -  Diagnosis of pre-transplant autoimmune liver disease (PBC, sclerosing cholangitis)

          -  Acute Liver Failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Umberto Cillo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Azienda Ospedaliera di Padova</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Umberto Cillo, MD</last_name>
    <phone>+390498218624</phone>
    <email>cillo@unipd.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laura Saracino, MSc</last_name>
    <phone>+390498218624</phone>
    <email>lasaracino@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ospedali Riuniti - Bergamo</name>
      <address>
        <city>Bergamo</city>
        <state>BG</state>
        <zip>24128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Colledan, MD</last_name>
      <phone>+39 035 269111</phone>
      <email>mcolledan@ospedaliriuniti.bergamo.it</email>
    </contact>
    <contact_backup>
      <last_name>Vittorio Corno, MD</last_name>
      <phone>+39 035 269111</phone>
      <email>vcorno@ospedaliriuniti.bergamo.it</email>
    </contact_backup>
    <investigator>
      <last_name>Michele Colledan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vittorio Corno, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Irccs Ospedale Maggiore Policlinico Di Milano</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giorgio Rossi, MD</last_name>
      <phone>+39 02 55031</phone>
      <email>giorgio.rossi@unimi.it</email>
    </contact>
    <contact_backup>
      <last_name>Paolo Reggiani, MD</last_name>
      <phone>+39 02 55031</phone>
      <email>paolo.reggiani@policlinico.mi.it</email>
    </contact_backup>
    <investigator>
      <last_name>Giorgio Rossi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paolo Reggiani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Ca` Granda-Niguarda - Milano</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luciano De Carlis, MD</last_name>
      <phone>+39 02 64441</phone>
      <email>Luciano.DeCarlis@ospedaleniguarda.it</email>
    </contact>
    <contact_backup>
      <last_name>Jacopo Mangoni, MD</last_name>
      <phone>+39 02 64441</phone>
      <email>jacopo.mangoni@libero.it</email>
    </contact_backup>
    <investigator>
      <last_name>Luciano De Carlis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jacopo Mangoni, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova</name>
      <address>
        <city>Padua</city>
        <state>PD</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Umberto Cillo, MD</last_name>
      <phone>+390498218624</phone>
      <email>cillo@unipd.it</email>
    </contact>
    <contact_backup>
      <last_name>Laura Saracino, MBS</last_name>
      <phone>+390498218624</phone>
      <email>lasaracino@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Umberto Cillo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giacomo Zanus, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniele Neri, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrizia Boccagni, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francesco D'Amico, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Enrico Gringeri, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alessandro Vitale, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pasquale Bonsignore, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paolo Feltracco, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dino Sgarabotto, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roberto Marchini, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Angelica Magrofuoco, CCTC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laura Saracino, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Gemelli Di Roma</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salvatore Agnes, MD</last_name>
      <phone>+39 06 3550 1928</phone>
      <email>salvatoreagnes@rm.unicatt.it</email>
    </contact>
    <contact_backup>
      <last_name>Erida Nure, MD</last_name>
      <phone>+39 06 3550 1928</phone>
      <email>eridanure@yahoo.it</email>
    </contact_backup>
    <investigator>
      <last_name>Erida Nure, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Salvatore Agnes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria S. Giovanni Battista-Molinette Di Torino</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mauro Salizzoni, MD</last_name>
      <phone>+39 011 633 1633</phone>
      <email>msalizzoni@molinette.piemonte.it</email>
    </contact>
    <contact_backup>
      <last_name>Francesco Lupo, MD</last_name>
      <phone>+39 011 633 1633</phone>
      <email>flupo@molinette.piemonte.it</email>
    </contact_backup>
    <investigator>
      <last_name>Mauro Salizzoni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francesco Lupo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria S. Maria Della Misericordia Di Udine</name>
      <address>
        <city>Udine</city>
        <state>UD</state>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabio Bresàdola, MD</last_name>
      <phone>+39 0432 5521</phone>
      <email>fabrizio.bresadola@dsc.uniud.it</email>
    </contact>
    <contact_backup>
      <last_name>Umberto Baccarani, MD</last_name>
      <phone>+39 0432 5521</phone>
      <email>umberto.baccarani@dsc.uniud.it</email>
    </contact_backup>
    <investigator>
      <last_name>Umberto Baccarani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fabio Bresàdola, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.fegatochirurgia.com/</url>
    <description>Hepatobiliary surgery and Liver Transplantation Unit, University Hospital of Padua (Italy)</description>
  </link>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2011</study_first_submitted>
  <study_first_submitted_qc>August 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2011</study_first_posted>
  <last_update_submitted>July 17, 2012</last_update_submitted>
  <last_update_submitted_qc>July 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera di Padova</investigator_affiliation>
    <investigator_full_name>Prof. Umberto Cillo</investigator_full_name>
    <investigator_title>Director of the Hepatobiliary Surgery and Liver Transplantation Unit</investigator_title>
  </responsible_party>
  <keyword>Liver Transplantation</keyword>
  <keyword>Graft Rejection</keyword>
  <keyword>Graft Survival</keyword>
  <keyword>Transplantation Immunology</keyword>
  <keyword>Anti-Rejection Therapy</keyword>
  <keyword>Immunosuppression</keyword>
  <keyword>Organ Transplantation</keyword>
  <keyword>Host vs Graft Reaction</keyword>
  <keyword>Gastroenterology</keyword>
  <keyword>Hepatology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

